TWI745323B - 脂化之肺炎鏈球菌抗原組合物、製備方法及用途 - Google Patents

脂化之肺炎鏈球菌抗原組合物、製備方法及用途 Download PDF

Info

Publication number
TWI745323B
TWI745323B TW105140949A TW105140949A TWI745323B TW I745323 B TWI745323 B TW I745323B TW 105140949 A TW105140949 A TW 105140949A TW 105140949 A TW105140949 A TW 105140949A TW I745323 B TWI745323 B TW I745323B
Authority
TW
Taiwan
Prior art keywords
fusion protein
pneumococcal
recombinant lipidated
psaa
protein
Prior art date
Application number
TW105140949A
Other languages
English (en)
Chinese (zh)
Other versions
TW201731866A (zh
Inventor
冷治湘
陳王學
莊再成
Original Assignee
加拿大國家研究委員會
財團法人國家衛生研究院
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 加拿大國家研究委員會, 財團法人國家衛生研究院 filed Critical 加拿大國家研究委員會
Publication of TW201731866A publication Critical patent/TW201731866A/zh
Application granted granted Critical
Publication of TWI745323B publication Critical patent/TWI745323B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6018—Lipids, e.g. in lipopeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
TW105140949A 2015-12-10 2016-12-09 脂化之肺炎鏈球菌抗原組合物、製備方法及用途 TWI745323B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562265525P 2015-12-10 2015-12-10
US62/265,525 2015-12-10

Publications (2)

Publication Number Publication Date
TW201731866A TW201731866A (zh) 2017-09-16
TWI745323B true TWI745323B (zh) 2021-11-11

Family

ID=59012415

Family Applications (2)

Application Number Title Priority Date Filing Date
TW105140949A TWI745323B (zh) 2015-12-10 2016-12-09 脂化之肺炎鏈球菌抗原組合物、製備方法及用途
TW107119885A TW201902921A (zh) 2015-12-10 2018-06-08 脂化之肺炎鏈球菌抗原組合物、製備方法及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW107119885A TW201902921A (zh) 2015-12-10 2018-06-08 脂化之肺炎鏈球菌抗原組合物、製備方法及用途

Country Status (7)

Country Link
US (2) US20180360943A1 (enExample)
EP (2) EP3387006A4 (enExample)
JP (1) JP6947727B2 (enExample)
CN (1) CN108884134A (enExample)
CA (2) CA3008042A1 (enExample)
TW (2) TWI745323B (enExample)
WO (2) WO2017096486A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
WO2018189372A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
CN110898217B (zh) * 2019-11-28 2023-03-28 遵义医科大学珠海校区 一种肺炎链球菌疫苗及其制备方法
IL297166A (en) 2020-04-09 2022-12-01 Valneva Austria Gmbh Compositions comprising three ospa fusion proteins for medical use
US20240026412A1 (en) * 2020-04-09 2024-01-25 Valneva Austria Gmbh Improved methods of producing a lipidated protein
CN119798389A (zh) * 2024-12-12 2025-04-11 中国人民解放军军事科学院军事医学研究院 一种含脂肪酸化修饰的重组MrkA蛋白的免疫组合物及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171661A2 (en) * 2012-05-15 2013-11-21 Subhash V Kapre Adjuvant formulations and methods

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4596792A (en) 1981-09-04 1986-06-24 The Regents Of The University Of California Safe vaccine for hepatitis containing polymerized serum albumin
US4599231A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4599230A (en) 1984-03-09 1986-07-08 Scripps Clinic And Research Foundation Synthetic hepatitis B virus vaccine including both T cell and B cell determinants
US4601903A (en) 1985-05-01 1986-07-22 The United States Of America As Represented By The Department Of Health And Human Services Vaccine against Neisseria meningitidis Group B serotype 2 invasive disease
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
US5854416A (en) * 1991-11-14 1998-12-29 The United States Of America As Represented By The Department Of Health And Human Services Streptococcus pneumoniae 37-KDA surface adhesin a protein and nucleic acids coding therefor
AU734488B2 (en) 1994-05-20 2001-06-14 Uab Research Foundation Mucosal administration of pneumococcal antigens
ZA964896B (en) * 1995-06-07 1997-01-08 Connaught Lab Expression of lipoproteins
GB9614700D0 (en) 1996-07-12 1996-09-04 Medical Res Council Over-expression of proteins in E.Coli
AU2003204215B2 (en) * 1998-02-03 2007-01-11 Aventis Pasteur Recombinant Lipidated PsaA Protein, Methods of Preparation and Use
NZ525674A (en) * 1998-02-03 2005-01-28 Ct Disease Contr & Prevention Recombinant lipidated PsaA protein, methods of preparation and use
US6903184B1 (en) 1998-03-02 2005-06-07 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Multiple antigenic peptides immunogenic against Streptococcus pneumonia
US6770321B2 (en) 2002-01-25 2004-08-03 Afg Industries, Inc. Method of making transparent articles utilizing protective layers for optical coatings
WO2006127020A1 (en) 2005-05-19 2006-11-30 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services, Centers For Disease Control And Prevention FUNCTIONAL EPITOPES OF STREPTOCOCCUS PNEUMONIAE PsaA ANTIGEN AND USES THEREOF
GB0714963D0 (en) 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
US7833776B2 (en) * 2007-12-12 2010-11-16 National Health Research Institutes Lipidating sequences and use thereof for producing lipidated proteins in E. coli
EP3017826A1 (en) * 2009-03-24 2016-05-11 Novartis AG Combinations of meningococcal factor h binding protein and pneumococcal saccharide conjugates
US8658176B2 (en) * 2009-06-22 2014-02-25 National Health Research Institutes Lipidated tumor-associated antigens and immunotherapeutic compositions
TW201221642A (en) * 2010-11-15 2012-06-01 Nat Health Research Institutes Method of producing lipidated polypeptides
US9765125B2 (en) * 2012-01-20 2017-09-19 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against Streptococcus pneumoniae
WO2014018904A1 (en) 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CN116603058A (zh) * 2015-03-26 2023-08-18 Gpn疫苗有限公司 链球菌疫苗

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013171661A2 (en) * 2012-05-15 2013-11-21 Subhash V Kapre Adjuvant formulations and methods

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
De et al., "Analysis of recombinant acylated pneumococcal surface adhesin A of Streptococcus pneumoniae by mass spectrometry", Archives of Biochemistry and Biophysics, Vol. 419, Issue 2, 15 November 2003, Pages 147-157.
De et al., "Analysis of recombinant acylated pneumococcal surface adhesin A of Streptococcus pneumoniae by mass spectrometry", Archives of Biochemistry and Biophysics, Vol. 419, Issue 2, 15 November 2003, Pages 147-157.; *
Wang et al., "Immune Responses to Recombinant Pneumococcal PsaA Antigen Delivered by a Live Attenuated Salmonella Vaccine", Infection And Immunity, Vol. 78, No. 7, July 2010, Pages 3258–3271 *

Also Published As

Publication number Publication date
JP6947727B2 (ja) 2021-10-13
WO2017096486A1 (en) 2017-06-15
EP3387006A4 (en) 2019-05-08
US10406221B2 (en) 2019-09-10
CA3066640A1 (en) 2018-12-13
TW201731866A (zh) 2017-09-16
EP3387006A1 (en) 2018-10-17
US20170368159A1 (en) 2017-12-28
EP3634981B1 (en) 2023-12-27
WO2018223243A1 (en) 2018-12-13
US20180360943A1 (en) 2018-12-20
CA3008042A1 (en) 2017-06-15
EP3634981A1 (en) 2020-04-15
CN108884134A (zh) 2018-11-23
TW201902921A (zh) 2019-01-16
JP2018537107A (ja) 2018-12-20
EP3634981A4 (en) 2020-12-16

Similar Documents

Publication Publication Date Title
EP3634981B1 (en) Lipidated streptococcus pneumoniae
JP6377907B2 (ja) クロストリジウム・ディフィシル（Ｃｌｏｓｔｒｉｄｉｕｍｄｉｆｆｉｃｉｌｅ）抗原
AU2019404924B2 (en) O-linked glycosylation recognition motifs
JP7535791B2 (ja) 肺炎球菌融合タンパク質ワクチン
CN104755099A (zh) 艰难梭菌抗原
US9125863B2 (en) Synergistic immunogenic fusion protein-polysaccharide conjugate
JP2021528059A (ja) グリコシル化されたＣｏｍＰピリンバリアント、製造方法及びその使用
EP4687967A1 (en) Meningococcal protein based vaccine formulations and methods formanufacturing thereof
JP5661744B2 (ja) 腸球菌由来のポリペプチド、及びワクチン接種のためのその使用
JP7833736B2 (ja) 複合糖質ワクチン
JP2018522978A (ja) 免疫原性組成物
US20230414738A1 (en) Haemophilus influenzae vaccine and methods of use
WO2024192346A1 (en) Immunogenic compositions
OA22209A (en) Meningococcal protein based vaccine formulations and methods for manufacturing thereof.
HK1172254A (en) Vaccines and compositions against streptococcus pneumoniae